Francesca Conradie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Conradie has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy Nel
University of the Witwatersrand
3 shared publications - Norbert Ndjeka
Drug-Resistant TB, TB & HIV Directorate, National Department of Health, Pretoria, South Africa and University of KwaZulu-Natal
3 shared publications - Rubeshan Perumal
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban 4001, South Africa
3 shared publications - Arifa Parker
Division of General Medicine, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
2 shared publications - Caroline Mudara
National Institute for Communicable Disease, Division of the National Health Laboratory Services
2 shared publications - Caroline Vika
National Institute for Communicable Disease, Division of the National Health Laboratory Services
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Effectiveness And Tolerability Of The Bpal-L Regimen In The South African Programmatic Setting: An Observational Cohort Study
Background: Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global TB control. The shorter (~6-month) all-oral bedaquiline-pretomanid-linezolid (BPaL) ± fluoroquinolone regimens have been endorsed by the WHO based on published trial data. However, programmatic data regarding its efficacy and safety remain limited.Methods: In this observational cohort study, we evaluated programmatic data from 8,736 RR-TB patients registered on the Electronic-Drug-Resistant-TB-Web-application (EDRWeb) between September 2022 and March 2025 across 5 high-burden South African provinces. We compared the ~6-month BPaL or BPaL with levofloxacin (BPaL/L) regimens with the superseded all-oral bedaquiline-linezolid-containing regimens (9–20-months). WHO-defined treatment-related outcomes were compared using regression models. Clinical characteristics and adverse events were compared descriptively, and time-to-event analyses were performed.Findings: 7504 (85·9%) eligible patients were included in the analysis. After adjusting for potential confounders (previous RR-TB, HIV, body-mass-index, haemoglobin and sputum smear positivity), BPaL/L were associated with significantly lower odds (95% CI) of unfavourable treatment outcomes [adjusted odds ratio (aOR) 0·46 (0·39 – 0·55); p<0·0001]. The proportion of unfavourable outcomes was lower with BPaL/L than with prior regimens [570/2965 (19·2%) vs 1543/4539 (34·0%); p<0·0001], driven primarily by fewer deaths [211/2965 (7·1%) vs 574/4539 (12·7%); p<0·0001] and less loss to follow-up [289/2965 (9·8%) vs 852/4539 (18·8%); p<0·0001]. Independent predictors of unfavourable outcome with BPaL/L were previous RR-TB, and moderate-to-severe anaemia (p<0·05). Fewer severe (Grade 3–5) adverse events were seen with BPaL/L [229/919 (24·9%) vs 528/1511 (34·9%); OR 0·62 (0·52 – 0·74); p<0·0001].Interpretation: In routine practice, 6-month BPaL/L regimens improved clinical outcomes and reduced severe toxicity compared to prior, longer all-oral regimens. However, one-in-five patients still experienced an unfavourable outcome, and treatment related adverse events remained common. These findings inform clinical management and underscore the need for more effective regimen development for DR-TB.Funding: SA Medical Research Council; European and Developing Countries Clinical Trials Partnership; National Research Foundation.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffectiveness And Tolerability Of The Bpal-L Regimen In The South African Programmatic Setting: An Observational Cohort Study
Background: Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global TB control. The shorter (~6-month) all-oral bedaquiline-pretomanid-linezolid (BPaL) ± fluoroquinolone regimens have been endorsed by the WHO based on published trial data. However, programmatic data regarding its efficacy and safety remain limited.Methods: In this observational cohort study, we evaluated programmatic data from 8,736 RR-TB patients registered on the Electronic-Drug-Resistant-TB-Web-application (EDRWeb) between September 2022 and March 2025 across 5 high-burden South African provinces. We compared the ~6-month BPaL or BPaL with levofloxacin (BPaL/L) regimens with the superseded all-oral bedaquiline-linezolid-containing regimens (9–20-months). WHO-defined treatment-related outcomes were compared using regression models. Clinical characteristics and adverse events were compared descriptively, and time-to-event analyses were performed.Findings: 7504 (85·9%) eligible patients were included in the analysis. After adjusting for potential confounders (previous RR-TB, HIV, body-mass-index, haemoglobin and sputum smear positivity), BPaL/L were associated with significantly lower odds (95% CI) of unfavourable treatment outcomes [adjusted odds ratio (aOR) 0·46 (0·39 – 0·55); p<0·0001]. The proportion of unfavourable outcomes was lower with BPaL/L than with prior regimens [570/2965 (19·2%) vs 1543/4539 (34·0%); p<0·0001], driven primarily by fewer deaths [211/2965 (7·1%) vs 574/4539 (12·7%); p<0·0001] and less loss to follow-up [289/2965 (9·8%) vs 852/4539 (18·8%); p<0·0001]. Independent predictors of unfavourable outcome with BPaL/L were previous RR-TB, and moderate-to-severe anaemia (p<0·05). Fewer severe (Grade 3–5) adverse events were seen with BPaL/L [229/919 (24·9%) vs 528/1511 (34·9%); OR 0·62 (0·52 – 0·74); p<0·0001].Interpretation: In routine practice, 6-month BPaL/L regimens improved clinical outcomes and reduced severe toxicity compared to prior, longer all-oral regimens. However, one-in-five patients still experienced an unfavourable outcome, and treatment related adverse events remained common. These findings inform clinical management and underscore the need for more effective regimen development for DR-TB.Funding: SA Medical Research Council; European and Developing Countries Clinical Trials Partnership; National Research Foundation.
- Open Access
- 18 June 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 501-509
Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone assessments. This phase 2 clinical trial assessed testicular safety of therapy with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in 26 adult males with drug‐resistant tuberculosis recruited from South Africa and Georgia. The study included 26 weeks of treatment followed by 52 weeks of safety monitoring until study week 78. The primary endpoint measured change in total sperm count from baseline at week 26, with secondary endpoints evaluating sperm concentration, semen volume, and reproductive hormone concentrations. Results demonstrated favorable testicular safety outcomes. Mean total sperm count increased from 48.8 to 68.8 × 10 6 per ejaculate by week 26. Fifteen participants (68%) showed increased sperm counts, while 17 (77%) exhibited higher sperm concentrations from baseline to week‐26 Thirteen participants (59%) experienced ≥ 50% improvement in both parameters. Two participants demonstrated > 50% decreases in total sperm count; however, sperm concentration reductions were < 50%, suggesting low semen volume as a factor. Testosterone levels increased from baseline, peaking at week 44, while inhibin B demonstrated steady increases, peaking at week 78. Follicle‐stimulating hormone and luteinizing hormone remained stable throughout the study period. All assessable participants achieved sputum culture conversion by week 12. Pharmacokinetic analysis revealed no correlation between pretomanid plasma concentrations and sperm count changes. These findings provide reassurance that pretomanid does not impair human spermatogenesis nor disrupt reproductive hormone homeostasis.
- 18 June 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 501-509
Open AccessPreserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen ( BPaMZ ) for Pulmonary Drug‐Resistant Tuberculosis
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone assessments. This phase 2 clinical trial assessed testicular safety of therapy with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in 26 adult males with drug‐resistant tuberculosis recruited from South Africa and Georgia. The study included 26 weeks of treatment followed by 52 weeks of safety monitoring until study week 78. The primary endpoint measured change in total sperm count from baseline at week 26, with secondary endpoints evaluating sperm concentration, semen volume, and reproductive hormone concentrations. Results demonstrated favorable testicular safety outcomes. Mean total sperm count increased from 48.8 to 68.8 × 10 6 per ejaculate by week 26. Fifteen participants (68%) showed increased sperm counts, while 17 (77%) exhibited higher sperm concentrations from baseline to week‐26 Thirteen participants (59%) experienced ≥ 50% improvement in both parameters. Two participants demonstrated > 50% decreases in total sperm count; however, sperm concentration reductions were < 50%, suggesting low semen volume as a factor. Testosterone levels increased from baseline, peaking at week 44, while inhibin B demonstrated steady increases, peaking at week 78. Follicle‐stimulating hormone and luteinizing hormone remained stable throughout the study period. All assessable participants achieved sputum culture conversion by week 12. Pharmacokinetic analysis revealed no correlation between pretomanid plasma concentrations and sperm count changes. These findings provide reassurance that pretomanid does not impair human spermatogenesis nor disrupt reproductive hormone homeostasis.
- Open Access
- 11 January 2023
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 24 (1) , 1522
Southern African HIV Clinicians Society 2023 Guideline for post-exposure prophylaxis: Updated recommendations
- 11 January 2023
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 24 (1) , 1522
Open AccessSouthern African HIV Clinicians Society 2023 Guideline for post-exposure prophylaxis: Updated recommendations
- Open Access
A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants
Background A third of people may experience persistent symptoms following COVID-19. With over 90% of South Africans having evidence of prior SARS-CoV-2 infection, it is likely that many people could be affected by Post COVID-19 Condition (PCC). Methods The was a prospective, longitudinal observational cohort study recruiting hospitalised and non-hospitalised participants, infected during the periods that Beta, Delta and Omicron BA.1 variants dominated in South Africa. Participants aged 18 years or older were randomly selected to undergo telephone assessment at 1, 3 and 6 months after hospital discharge or laboratory-confirmed SARS-CoV-2 infection. Participants were assessed using a standardised questionnaire for evaluation of symptoms and health-related quality of life. We used negative binomial regression models to determine factors associated with the presence of ≥1 symptoms at 6 months. Findings Among hospitalised and non-hospitalised participants, 46.7% (1,227/2,626) and 18.5% (199/1,074) had ≥1 symptoms at 6 months (p=Interpretation The study revealed a high prevalence of persistent symptoms among South African participants at 6 months although decreased risk for PCC among participants infected during the Omicron BA.1 wave. These findings have serious implications for countries with resource-constrained healthcare systems. Funding Bill & Melinda Gates Foundation, UK Foreign, Commonwealth & Development Office, and Wellcome.
Open AccessA cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants
Background A third of people may experience persistent symptoms following COVID-19. With over 90% of South Africans having evidence of prior SARS-CoV-2 infection, it is likely that many people could be affected by Post COVID-19 Condition (PCC). Methods The was a prospective, longitudinal observational cohort study recruiting hospitalised and non-hospitalised participants, infected during the periods that Beta, Delta and Omicron BA.1 variants dominated in South Africa. Participants aged 18 years or older were randomly selected to undergo telephone assessment at 1, 3 and 6 months after hospital discharge or laboratory-confirmed SARS-CoV-2 infection. Participants were assessed using a standardised questionnaire for evaluation of symptoms and health-related quality of life. We used negative binomial regression models to determine factors associated with the presence of ≥1 symptoms at 6 months. Findings Among hospitalised and non-hospitalised participants, 46.7% (1,227/2,626) and 18.5% (199/1,074) had ≥1 symptoms at 6 months (p=Interpretation The study revealed a high prevalence of persistent symptoms among South African participants at 6 months although decreased risk for PCC among participants infected during the Omicron BA.1 wave. These findings have serious implications for countries with resource-constrained healthcare systems. Funding Bill & Melinda Gates Foundation, UK Foreign, Commonwealth & Development Office, and Wellcome.
- Open Access
Post COVID-19 Condition in South Africa: 3-month follow-up after hospitalisation with SARS-CoV-2
Background Post COVID-19 Condition (PCC) as defined by WHO refers to a wide range of new, returning, or ongoing health problems experienced by COVID-19 survivors, and represents a rapidly emerging public health priority. We aimed to establish how this developing condition has impacted patients in South Africa and which population groups are at risk. Methods In this prospective cohort study, participants ≥18 years who had been hospitalised with laboratory-confirmed SARS-CoV-2 infection during the second and third wave between December 2020 and August 2021 underwent telephonic follow-up assessment up at one-month and three-months after hospital discharge. Participants were assessed using a standardised questionnaire for the evaluation of symptoms, functional status, health-related quality of life and occupational status. Multivariable logistic regression models were used to determine factors associated with PCC. Findings In total, 1,873 of 2,413 (78%) enrolled hospitalised COVID-19 participants were followed up at three-months after hospital discharge. Participants had a median age of 52 years (IQR 41-62) and 960 (51.3%) were women. At three-months follow-up, 1,249 (66.7%) participants reported one or more persistent COVID-related symptom(s), compared to 1,978/2,413 (82.1%) at one-month post-hospital discharge. The most common symptoms reported were fatigue (50.3%), shortness of breath (23.4%), confusion or lack of concentration (17.5%), headaches (13.8%) and problems seeing/blurred vision (10.1%). On multivariable analysis, factors associated with new or persistent symptoms following acute COVID-19 were age ≥65 years [adjusted odds ratio (aOR) 1.62; 95%confidence interval (CI) 1.00-2.61]; female sex (aOR 2.00; 95% CI 1.51-2.65); mixed ethnicity (aOR 2.15; 95% CI 1.26-3.66) compared to black ethnicity; requiring supplemental oxygen during admission (aOR 1.44; 95% CI 1.06-1.97); ICU admission (aOR 1.87; 95% CI 1.36-2.57); pre-existing obesity (aOR 1.44; 95% CI 1.09-1.91); and the presence of ≥4 acute symptoms (aOR 1.94; 95% CI 1.19-3.15) compared to no symptoms at onset. Interpretation The majority of COVID-19 survivors in this cohort of previously hospitalised participants reported persistent symptoms at three-months from hospital discharge, as well as a significant impact of PCC on their functional and occupational status. The large burden of PCC symptoms identified in this study emphasises the need for a national health strategy. This should include the development of clinical guidelines and training of health care workers, in identifying, assessing and caring for patients affected by PCC, establishment of multidisciplinary national health services, and provision of information and support to people who suffer from PCC.
Open AccessPost COVID-19 Condition in South Africa: 3-month follow-up after hospitalisation with SARS-CoV-2
Background Post COVID-19 Condition (PCC) as defined by WHO refers to a wide range of new, returning, or ongoing health problems experienced by COVID-19 survivors, and represents a rapidly emerging public health priority. We aimed to establish how this developing condition has impacted patients in South Africa and which population groups are at risk. Methods In this prospective cohort study, participants ≥18 years who had been hospitalised with laboratory-confirmed SARS-CoV-2 infection during the second and third wave between December 2020 and August 2021 underwent telephonic follow-up assessment up at one-month and three-months after hospital discharge. Participants were assessed using a standardised questionnaire for the evaluation of symptoms, functional status, health-related quality of life and occupational status. Multivariable logistic regression models were used to determine factors associated with PCC. Findings In total, 1,873 of 2,413 (78%) enrolled hospitalised COVID-19 participants were followed up at three-months after hospital discharge. Participants had a median age of 52 years (IQR 41-62) and 960 (51.3%) were women. At three-months follow-up, 1,249 (66.7%) participants reported one or more persistent COVID-related symptom(s), compared to 1,978/2,413 (82.1%) at one-month post-hospital discharge. The most common symptoms reported were fatigue (50.3%), shortness of breath (23.4%), confusion or lack of concentration (17.5%), headaches (13.8%) and problems seeing/blurred vision (10.1%). On multivariable analysis, factors associated with new or persistent symptoms following acute COVID-19 were age ≥65 years [adjusted odds ratio (aOR) 1.62; 95%confidence interval (CI) 1.00-2.61]; female sex (aOR 2.00; 95% CI 1.51-2.65); mixed ethnicity (aOR 2.15; 95% CI 1.26-3.66) compared to black ethnicity; requiring supplemental oxygen during admission (aOR 1.44; 95% CI 1.06-1.97); ICU admission (aOR 1.87; 95% CI 1.36-2.57); pre-existing obesity (aOR 1.44; 95% CI 1.09-1.91); and the presence of ≥4 acute symptoms (aOR 1.94; 95% CI 1.19-3.15) compared to no symptoms at onset. Interpretation The majority of COVID-19 survivors in this cohort of previously hospitalised participants reported persistent symptoms at three-months from hospital discharge, as well as a significant impact of PCC on their functional and occupational status. The large burden of PCC symptoms identified in this study emphasises the need for a national health strategy. This should include the development of clinical guidelines and training of health care workers, in identifying, assessing and caring for patients affected by PCC, establishment of multidisciplinary national health services, and provision of information and support to people who suffer from PCC.
- Open Access
- 15 October 2020
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 21 (1)
Southern African HIV Clinicians Society guidelines for solid organ transplantation in human immunodeficiency virus: An evidence-based framework for human immunodeficiency virus-positive donors and recipients
- 15 October 2020
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 21 (1)
Open AccessSouthern African HIV Clinicians Society guidelines for solid organ transplantation in human immunodeficiency virus: An evidence-based framework for human immunodeficiency virus-positive donors and recipients
- Open Access
- 11 October 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 104 (1) , 24-6
Prevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB
Background. Symptomatic symmetrical peripheral neuropathy (SSPN) is common in patients with HIV infection. It is also a common adverse event associated with both tuberculosis (TB) treatment and antiretroviral therapy (ART), particularly stavudine. While tenofovir is the one of recommended first-line nucleotide reverse transcriptase inhibitors (NRTIs), there is a risk of nephrotoxicity when using tenofovir together with the aminoglycosides needed to treat multidrug-resistant (MDR) TB. Thus, stavudine is often chosen as a treatment option for the HIV-infected MDR TB patient. Objective. To assess whether use of stavudine both before and during treatment for MDR TB increased the prevalence and incidence of SSPN. Method. MDR TB patients at Sizwe Tropical Disease Hospital were examined for signs of prevalent SSPN. Age, gender, HIV status, alcohol use, TB and HIV treatment regimens both prior to admission and current, and concomitant medications were recorded. Results. In this cohort of 246 patients, we found that 24.4% of patients with MDR TB had SSPN at time of admission for treatment of MDR TB. They were more likely to be HIV-infected (odds ratio (OR) 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) exposure to stavudine (OR 1.81; 95% CI 0.90 - 3.63). Incident SSPN occurred in 17% of patients and was associated with older age (hazard ratio (HR) 3.00; 95% CI 1.30 - 6.89) and exposure to terizidone (HR 2.98; 95% CI 0.94 to 4.61) or, to a lesser extent, with stavudine (crude HR 1.62; 95% CI 0.65 - 4.01) in the first 6 months of MDR TB treatment. This common adverse event emphasises the need for the development of less toxic drugs for the treatment of MDR TB.
- 11 October 2013
- Published by South African Medical Association NPC in South African Medical Journal
- Vol. 104 (1) , 24-6
Open AccessPrevalence and incidence of symmetrical symptomatic peripheral neuropathy in patients with multidrug-resistant TB
Background. Symptomatic symmetrical peripheral neuropathy (SSPN) is common in patients with HIV infection. It is also a common adverse event associated with both tuberculosis (TB) treatment and antiretroviral therapy (ART), particularly stavudine. While tenofovir is the one of recommended first-line nucleotide reverse transcriptase inhibitors (NRTIs), there is a risk of nephrotoxicity when using tenofovir together with the aminoglycosides needed to treat multidrug-resistant (MDR) TB. Thus, stavudine is often chosen as a treatment option for the HIV-infected MDR TB patient. Objective. To assess whether use of stavudine both before and during treatment for MDR TB increased the prevalence and incidence of SSPN. Method. MDR TB patients at Sizwe Tropical Disease Hospital were examined for signs of prevalent SSPN. Age, gender, HIV status, alcohol use, TB and HIV treatment regimens both prior to admission and current, and concomitant medications were recorded. Results. In this cohort of 246 patients, we found that 24.4% of patients with MDR TB had SSPN at time of admission for treatment of MDR TB. They were more likely to be HIV-infected (odds ratio (OR) 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) exposure to stavudine (OR 1.81; 95% CI 0.90 - 3.63). Incident SSPN occurred in 17% of patients and was associated with older age (hazard ratio (HR) 3.00; 95% CI 1.30 - 6.89) and exposure to terizidone (HR 2.98; 95% CI 0.94 to 4.61) or, to a lesser extent, with stavudine (crude HR 1.62; 95% CI 0.65 - 4.01) in the first 6 months of MDR TB treatment. This common adverse event emphasises the need for the development of less toxic drugs for the treatment of MDR TB.